Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer

Huber, Rudolf M.; Reck, Martin; Thomas, Michael

doi:10.1183/09031936.00143112

Cited by 13 publications

(6 citation statements)

References 107 publications

(102 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to the 8.4% (40/478) who were untreated in progression interval 1, the rates in progression intervals 2 and 3 were far larger (27.3 and 26%, respectively). Further underscoring the unmet need is the fact that the majority of patients who received initial cCRT went on to experience disease progression, a finding that has been observed in other research in this population [16]. This outcome indicates a clear need for more effective treatment options that can be used in subsequent regimens following cCRT to delay or prevent subsequent disease progression.…”

Section: Discussionmentioning

confidence: 79%

Real-world Treatment Patterns Among Patients with Unresected Stage III Non-Small-Cell Lung Cancer

et al. 2019

View full text Add to dashboard Cite

Aim: Little is known about recent treatment patterns among patients with unresected stage III NSCLC in the real world. This retrospective study used medical records from USA community oncology practices to address this knowledge gap. Materials & methods: Eligible patients were stage III NSCLC adults diagnosed between 1 January 2011 and 1 March 2016 without surgical resection. Treatment patterns were assessed across three progression intervals, from stage III diagnosis through third progression. Results: The most common regimen in interval 1 was platinum doublet chemotherapy + radiation therapy, in interval 2 was chemotherapy only, and in interval 3 was non-platinum chemotherapy monotherapy. Conclusion: Most patients were treated following national guidelines, but important unmet needs remain.

show abstract

Section: Discussionmentioning

confidence: 79%

Real-world Treatment Patterns Among Patients with Unresected Stage III Non-Small-Cell Lung Cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Since most lung tumors are diagnosed only when they reach advanced stages, standard treatments, namely surgical resection, radio-and chemotherapy, are mostly ineffective. Hence recent efforts, including the development of immunotherapy agents, reflect the urgent need for more effective, specific therapeutic approaches (30–33). The present study shows that SapC-DOPS, a liposomal biotherapeutic agent composed of a lysosomal hydrolase co-activator (SapC) and a phospholipid (DOPS), induces apoptosis in lung tumor cells in vitro and delays the growth of lung cancer xenografts in vivo .…”

Section: Discussionmentioning

confidence: 99%

SapC–DOPS Nanovesicles as Targeted Therapy for Lung Cancer

Zhao

Chu

Blanco

et al. 2015

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Lung cancer is the deadliest type of cancer for both men and women. In this study, we evaluate the in vitro and in vivo efficacy of a biotherapeutic agent composed of a lysosomal protein (Saposin C, SapC) and a phospholipid (dioleoylphosphatidylserine, DOPS) which can be assembled into nanovesicles (SapC-DOPS) with selective antitumor activity. SapC-DOPS targets phosphatidylserine, an anionic phospholipid preferentially exposed in the surface of cancer cells and tumor-associated vasculature. Since binding of SapC to phosphatidylserine is favored at acidic pHs, and the latter characterizes the milieu of many solid tumors, we tested the effect of pH on the binding capacity of SapC-DOPS to lung tumor cells. Results showed that SapC-DOPS binding to cancer cells was more pronounced at low pH. Viability assays on a panel of human lung tumor cells showed that SapC-DOPS cytotoxicity was positively correlated with cell surface phosphatidylserine levels, whereas mitochondrial membrane potential measurements were consistent with apoptosis-related cell death. Using a fluorescence tracking method in live mice, we show that SapC-DOPS specifically targets human lung cancer xenografts, and that systemic therapy with SapC-DOPS induces tumor apoptosis and significantly inhibits tumor growth. These results suggest that SapC-DOPS nanovesicles are a promising treatment option for lung cancer.

show abstract

“…Lung cancer therapy will involve screening patients for biomarkers [39-42]. However, there are controversies regarding the screening procedures.…”

Section: Egfr Detection Methodsmentioning

confidence: 99%

Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors

2015

View full text Add to dashboard Cite

Expression of the EGF receptors (EGFRs) is abnormally high in many types of cancer, including 25% of lung cancers. Successful treatments target mutations in the EGFR tyrosine kinase domain with EGFR tyrosine kinase inhibitors (TKIs). However, almost all patients develop resistance to this treatment, and acquired resistance to first-generation TKI has prompted the clinical development of a second generation of EGFR TKI. Because of the development of resistance to treatment of TKIs, there is a need to collect genomic information about EGFR levels in non-small-cell lung cancer patients. Herein, we focus on current molecular targets that have therapies available as well as other targets for which therapies will be available in the near future.

show abstract

Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer

Cited by 13 publications

References 107 publications

Real-world Treatment Patterns Among Patients with Unresected Stage III Non-Small-Cell Lung Cancer

Real-world Treatment Patterns Among Patients with Unresected Stage III Non-Small-Cell Lung Cancer

SapC–DOPS Nanovesicles as Targeted Therapy for Lung Cancer

Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors

Contact Info

Product

Resources

About